The therapeutic utility of such an approach was recently demonstrated for Dravet syndrome, where CRISPRa was used to upregulate the expression of the WT Scn1a allele by ~ 50%, and improved the epileptic phenotype [42]. This evidence concerns the gene SCN1A and Dravet syndrome.